{"id":"csf3r","name":"G-CSF receptor (CSF3R)","symbol":"CSF3R","route":"/targets/csf3r/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2439","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119535","uniprot":"https://www.uniprot.org/uniprotkb/Q99062/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q99062","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1996","open-targets":"https://platform.opentargets.org/target/ENSG00000119535","civic":"https://civicdb.org/genes/1441/summary","oncokb":"https://www.oncokb.org/gene/CSF3R","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CSF3R","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CSF3R","depmap":"https://depmap.org/portal/gene/CSF3R?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000119535-CSF3R","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1441","omim":"https://www.omim.org/entry/138971"}],"products":[{"id":"eflapegrastim","name":"Eflapegrastim","status":"approved","modality":"Long-acting G-CSF fused to an antibody Fc fragment, once per chemotherapy cycle","route":"/drugs/eflapegrastim/"},{"id":"lenograstim","name":"Lenograstim","status":"established","modality":"Recombinant glycosylated G-CSF, injection","route":"/drugs/lenograstim/"}],"trials":[{"id":"nct00431080","name":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","nct":"NCT00431080","phase":"3","status":"completed"},{"id":"nct01985724","name":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","nct":"NCT01985724","phase":"3","status":"completed"},{"id":"nct00615602","name":"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","nct":"NCT00615602","phase":"3","status":"completed"},{"id":"nct04570423","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","nct":"NCT04570423","phase":"2","status":"recruiting"}],"pathways":[],"companies":["chugai","spectrum-pharmaceuticals"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}